UPDATE 1-Novo Nordisk says Victoza cleared for EU market
* Diabetes treatment Victoza gets EU marketing approval
* Approval was expected after EU drugs agency recommendation
* Launch planned for this year and in 2010
* Novo says approval does not change 2009 outlook
(Adds details, quotes, share price, background)
COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's (NOVOb.CO: Quote, Profile, Research) diabetes drug Victoza, a key driver for future sales, has won European Commission approval for marketing across the European Union, the company said on Friday.
The move had been expected, following a positive opinion from the European Medicines Agency on April23.
"The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults," Novo Nordisk said in a statement, calling it an "important milestone".
The company will launch Victoza -- which is the brand name for liraglutide -- in Britain, Germany and Denmark this summer and in other European markets in the second half of 2009 and throughout 2010, Novo Nordisk said. Continued...
UK joins G20 push for world levy on banks
Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change. Full Article | Full Coverage
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
